Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.31 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | CASP3 | P42574 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.30 |
| ▸ | RELA | Q04206 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.30 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.30 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31283290 | 1.00 | MAOB (0.33) | MAOBGRM2HTTALDH1A1ACHE | |
| SCHEMBL20819712 | 0.83 | ALDH1A1 (0.39) | GRM2ALDH1A1PDPK1NPC1RAB9A | |
| SCHEMBL6943096 | 0.74 | IDO1 (0.35) | ALDH1A1 | |
| SCHEMBL18796222 | 0.73 | LMNA (0.36) | HTTALDH1A1ACHETDP1NPC1 | |
| SCHEMBL9431321 | 0.73 | ACHE (0.32) | ACHECES2CES1 | |
| SCHEMBL24125843 | 0.73 | HSD11B1 (0.38) | ALDH1A1PDPK1NPC1LMNARAB9A | |
| SCHEMBL2858470 | 0.73 | ALOX5AP (0.30) | — | |
| SCHEMBL5558831 | 0.73 | ALDH1A1 (0.36) | MAOBALDH1A1ACHETDP1NPC1 | |
| SCHEMBL2832076 | 0.72 | ERN1 (0.52) | ALDH1A1NFE2L2TDP1LMNAKMT2A | |
| SCHEMBL15091555 | 0.70 | ACHE (0.38) | ALDH1A1ACHENFE2L2NPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116745269-A | Dihydroquinazolin-2-one derivatives as selective cytotoxic agents for the treatment of HIV | 默沙东有限责任公司 | 2023-09-12 | — | — | CN | disclosed |
| EP-2734505-A1 | 3-(FLUORVINYL)PYRAZOLES AND THE USE THEREOF | Bayer Intellectual Property GmbH (DE) | 2014-05-28 | — | — | EP | disclosed |
| US-20130150325-A1 | 3-(Fluorovinyl)pyrazoles and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-13 | — | — | US | disclosed |
| EP-2569309-A1 | HYDROXYALKYL BENZYL PYRAZOLES, AND USE THEREOF FOR THE TREATMENT OF HYPERPROLIFERATIVE AND ANGIOGENIC DISEASES | Bayer Intellectual Property GmbH (DE) | 2013-03-20 | — | — | EP | disclosed |
| WO-2013011033-A1 | 3-(FLUORVINYL)PYRAZOLES AND THE USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-01-24 | — | — | WO | disclosed |
| WO-2011141325-A1 | HYDROXYALKYL BENZYL PYRAZOLES, AND USE THEREOF FOR THE TREATMENT OF HYPERPROLIFERATIVE AND ANGIOGENIC DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-11-17 | — | — | WO | disclosed |
| US-20090124607-A1 | Novel Bicyclic Sulfonamides for Use as Glucocorticoid Receptor Modulators in the Treatment of Inflammatory Diseases | ASTRAZENECA AB (SE) | 2009-05-14 | — | — | US | disclosed |
| EP-1940800-A1 | NOVEL BICYCLIC SULFONAMIDES FOR USE AS GLUCOCORTICOID RECEPTOR MODULATORS IN THE TREATMENT OF INFLAMMATORY DISEASES | Astra Zeneca AB (SE) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007046747-A1 | NOVEL BICYCLIC SULFONAMIDES FOR USE AS GLUCOCORTICOID RECEPTOR MODULATORS IN THE TREATMENT OF INFLAMMATORY DISEASES | ASTRAZENECA AB (SE) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150325-A1 | 3-(Fluorovinyl)pyrazoles and their use | VHL, HIF1AN, HIF1A | MAOB 1537/4885GRM2 2837/4885HTT 3493/4885 |
| US-20090124607-A1 | Novel Bicyclic Sulfonamides for Use as Glucocorticoid Receptor Modulators in the Treatment of Inflammatory Diseases | NR3C1, NR3C2, MC2R | MAOB 4237/4885GRM2 80/4885HTT 4214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.